Sanofi taps Charmeil as emerging-markets vax chief; Novartis' Afintor delays breast cancer;

@FiercePharma: Drug, device reps add iPads to tool belt. Article | Follow @FiercePharma

> Sanofi-Aventis has named a new emerging markets-focused chief for its vaccines division, Olivier Charmeil, who's currently responsible for pharmaceutical operations in Asia-Pacific and Japan. Story

> Swiss drugmaker Novartis said the addition of its Afinitor to hormonal therapy delayed disease progression in breast cancer in a mid-phase study, bringing the potential blockbuster one step closer to gaining approval for this very common form of cancer. Report

> Dutch biotech firm Crucell's chief executive urged shareholders to accept U.S. healthcare group Johnson & Johnson's long-awaited 1.75 billion euro bid. News

> Shares of Adcock Ingram tumbled as much as 4.1 percent after the drugmaker said South Africa would ban three drugs that contributed $29 million to its sales due to safety concerns. Story

> European drugs regulators said they are starting a review of the safety of somatropin-containing medicines after a study suggested the growth hormone treatments increased the risk of death. Report

Biotech News

 @FierceBiotech: Orexigen endorsement raises expectations on obesity drug deals. Story  | Follow @FierceBiotech

 @JohnCFierce: Shrinking and forced to give up China buyout, investors now pushing Charles River Labs to put itself up for sale. News | Follow @JohnCFierce

> Restructuring rejection forces Molecular Insight to declare bankruptcy. Item 

> MorphoSys unit, Pfizer ink Slonomics pact. Story 

> Pfizer halts Phase III trial, withdraws Thelin. Report 

> Ramius sweetens offer for Cypress. News 

And Finally... Indian drugmakers are experimenting with design to distinguish products from round and rectangular pills, adopting dumbbell, flower, lollipop or symbol X shapes. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.